Cover Image
市場調查報告書

Vybion, Inc.:產品平台分析

Vybion, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 305690
出版日期 內容資訊 英文 20 Pages
訂單完成後即時交付
價格
Back to Top
Vybion, Inc.:產品平台分析 Vybion, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 20 Pages
簡介

Vybion, Inc.是開發階段的製藥公司。正在製造人體單株抗體醫藥品。

本報告提供Vybion, Inc.之調查分析,提供您治療藥的開發平台最新資訊,加上各開發階段比較分析,藥物標的·作用機制·給藥途徑·各分子類型的治療藥評估,也包含最新消息和新聞稿,後期階段·中止的計劃等系統性資訊。

目錄

Vybion, Inc.的基本資料

  • Vybion, Inc.概要
  • 主要資訊
  • 企業資料

Vybion, Inc.:研究開發概要

  • 主要的治療領域

Vybion, Inc.:開發平台檢驗

  • 開發中產品:各開發階段
  • 開發中產品:單獨療法

Vybion, Inc.:開發中產品的概要

  • 初期階段的開發中產品

Vybion, Inc.:藥物簡介

  • INT-41
  • Antibodies for Insulin Resistant Diabetes
  • Antibodies for Unknown Indication

Vybion, Inc.:開發平台分析

  • 開發中產品:標的別
  • 開發中產品:各分子類型
  • 開發中產品:各作用機制

Vybion, Inc.:所在地與子公司

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07148CDB

Summary

Global Markets Direct's, 'Vybion, Inc. - Product Pipeline Review - 2015', provides an overview of the Vybion, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vybion, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Vybion, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vybion, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vybion, Inc.'s pipeline products

Reasons to buy

  • Evaluate Vybion, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vybion, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vybion, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vybion, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vybion, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Vybion, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Vybion, Inc. Snapshot
    • Vybion, Inc. Overview
    • Key Information
    • Key Facts
  • Vybion, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Vybion, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Vybion, Inc. - Pipeline Products Glance
    • Vybion, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Vybion, Inc. - Drug Profiles
    • INT-41
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibodies for Insulin Resistant Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antibodies for Unknown Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vybion, Inc. - Pipeline Analysis
  • Vybion, Inc. - Pipeline Products by Target
  • Vybion, Inc. - Pipeline Products by Molecule Type
  • Vybion, Inc. - Pipeline Products by Mechanism of Action
  • Vybion, Inc. - Locations and Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Vybion, Inc., Key Information
  • Vybion, Inc., Key Facts
  • Vybion, Inc. - Pipeline by Indication, 2015
  • Vybion, Inc. - Pipeline by Stage of Development, 2015
  • Vybion, Inc. - Monotherapy Products in Pipeline, 2015
  • Vybion, Inc. - Preclinical, 2015
  • Vybion, Inc. - Discovery, 2015
  • Vybion, Inc. - Pipeline by Target, 2015
  • Vybion, Inc. - Pipeline by Molecule Type, 2015
  • Vybion, Inc. - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Vybion, Inc. - Pipeline by Top 10 Indication, 2015
  • Vybion, Inc. - Pipeline by Stage of Development, 2015
  • Vybion, Inc. - Monotherapy Products in Pipeline, 2015
  • Vybion, Inc. - Pipeline by Top 10 Target, 2015
  • Vybion, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Vybion, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top